Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2018, Article ID 6079101, 11 pages
https://doi.org/10.1155/2018/6079101
Research Article

Portulaca Extract Attenuates Development of Dextran Sulfate Sodium Induced Colitis in Mice through Activation of PPARγ

1Department of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, China
2The School of Medicine, Soochow University, Suzhou 215006, China
3Department of Gastroenterology, Shanghai Tenth Hospital, School of Clinical Medicine, Nanjing Medical University, Shanghai 200072, China
4Department of Immunology and Microbiology, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
5The Eye Hospital, Wenzhou Medical University, Wenzhou City, Zhejiang 325027, China

Correspondence should be addressed to Qi Dai; nc.ca.eye.liam@qd, Yuejuan Zheng; moc.361@21467714631, and Jie Lu; moc.liamtoh@nersinnek

Received 27 July 2017; Revised 14 September 2017; Accepted 28 November 2017; Published 1 February 2018

Academic Editor: Yuewen Gong

Copyright © 2018 Rui Kong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. D. Kappelman, S. L. Rifas-Shiman, C. Q. Porter et al., “Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults,” Gastroenterology, vol. 135, no. 6, pp. 1907–1913, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. S. C. Ng, C. N. Bernstein, M. H. Vatn et al., “Geographical variability and environmental risk factors in inflammatory bowel disease,” Gut, vol. 62, no. 4, pp. 630–649, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. B. A. Hendrickson, R. Gokhale, and J. H. Cho, “Clinical aspects and pathophysiology of inflammatory bowel disease,” Clinical Microbiology Reviews, vol. 15, no. 1, pp. 79–94, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. M. K. Uddin, A. S. Juraimi, M. E. Ali, and M. R. Ismail, “Evaluation of antioxidant properties and mineral composition of purslane (Portulaca oleracea L.) at different growth stages,” International Journal of Molecular Sciences, vol. 13, no. 8, pp. 10257–10267, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. C.-J. Chen, W.-Y. Wang, X.-L. Wang et al., “Anti-hypoxic activity of the ethanol extract from Portulaca oleracea in mice,” Journal of Ethnopharmacology, vol. 124, no. 2, pp. 246–250, 2009. View at Publisher · View at Google Scholar
  6. L. F. Hu, X. Y. Xu, and B. Q. Wang, “Research and utilization situation of PortulacaOleracea L. in China,” Journal of Pharmacy Practice and Community Medicine, vol. 20, pp. 315-316, 2003. View at Google Scholar
  7. L. Xiang, D. Xing, W. Wang, R. Wang, Y. Ding, and L. Du, “Alkaloids from Portulaca oleracea L.,” Phytochemistry, vol. 66, no. 21, pp. 2595–2601, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. A. N. Rashed, F. U. Afifi, and A. M. Disi, “Simple evaluation of the wound healing activity of a crude extract of Portulaca oleracea L. (growing in Jordan) in Mus musculus JVI-1,” Journal of Ethnopharmacology, vol. 88, no. 2-3, pp. 131–136, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. X. J. Zhang, Y. B. Ji, QuZh Y., and et al., “Experimental studies on antibiotic functions of Portulacaoleracea L. in vitro,” Chinese Journal of Microbiology and Immunology, vol. 14, pp. 277–280, 2002. View at Google Scholar
  10. W. Wang, L. Gu, L. Dong, X. Wang, C. Ling, and M. Li, “Protective effect of Portulacaoleracea extracts on hypoxic nerve tissue and its mechanism,” Asia Pacific Journal of Clinical Nutrition, pp. 227–233, 2007. View at Google Scholar
  11. K. Y. Musa, A. Ahmed, G. Ibrahim et al., “Toxicity studies on the methanolic extract of Portulaca oleracea L. (Fam. Portulacaceae),” Journal of Biological Sciences, vol. 7, no. 7, pp. 1293–1295, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. A. T. Reddy, S. P. Lakshmi, and R. C. Reddy, “PPAR γ in Bacterial Infections: A Friend or Foe?” PPAR Research, vol. 2016, Article ID 7963540, 2016. View at Publisher · View at Google Scholar · View at Scopus
  13. T. D. Hinds, K. John, L. McBeth, C. J. Trabbic, and E. R. Sanchez, “Timcodar (VX-853) Is a Non-FKBP12 Binding Macrolide Derivative That Inhibits PPAR γ and Suppresses Adipogenesis,” PPAR Research, vol. 2016, Article ID 6218637, 2016. View at Publisher · View at Google Scholar · View at Scopus
  14. G. D. Demetri, C. D. Fletcher, E. Mueller et al., “Induction of solid tumor differentiation by the peroxisome proliferator- activated receptor-γ ligand troglitazone in patients with liposarcoma,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 96, no. 7, pp. 3951–3956, 1999. View at Publisher · View at Google Scholar · View at Scopus
  15. T. Kubota, K. Koshizuka, E. A. Williamson, and et al., “Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo,” Cancer Research, vol. 58, no. 15, pp. 3344–3352, 1998. View at Google Scholar
  16. S. P. Lakshmi, A. T. Reddy, A. Banno, and R. C. Reddy, “PPAR Agonists for the Prevention and Treatment of Lung Cancer,” PPAR Research, vol. 2017, pp. 1–8, 2017. View at Publisher · View at Google Scholar
  17. G. Chinetti, S. Lestavel, V. Bocher, and et al., “PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway,” Nature Medicine, vol. 7, no. 1, pp. 53–58, 2001. View at Google Scholar
  18. L. F. da Rocha Junior, A. T. Dantas, Â. L. B. P. Duarte, M. J. B. de Melo Rego, I. D. R. Pitta, and M. G. D. R. Pitta, “PPARγ agonists in adaptive immunity: what do immune disorders and their models have to tell us?” PPAR Research, vol. 2013, Article ID 519724, 9 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, “The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation,” Nature, vol. 391, no. 6662, pp. 79–82, 1998. View at Publisher · View at Google Scholar · View at Scopus
  20. W. Hozayen, M. Bastawy, and H. Elshafeey, “Effects of Aqueous Purslane (PortulacaOleracea) Extractand Fish Oil on Gentamicin Nephrotoxicity in Albino Rats,” Natural Sciences, vol. 9, pp. 47–62, 2011. View at Google Scholar
  21. A. N. Ananthakrishnan, E. L. McGinley, and D. G. Binion, “Does it matter where you are hospitalized for inflammatory bowel disease? A nationwide analysis of hospital volume,” American Journal of Gastroenterology, vol. 103, no. 11, pp. 2789–2798, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. D. Bojic, Z. Radojicic, M. Nedeljkovic-Protic, M. Al-Ali, D. P. Jewell, and S. P. L. Travis, “Long-term outcome after admission for acute severe ulcerative colitis in Oxford: The 1992-1993 cohort,” Inflammatory Bowel Diseases, vol. 15, no. 6, pp. 823–828, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Kang, Y. Jeon, K. Moon et al., Journal of Medicinal Food, vol. 20, no. 7, pp. 667–675, 2017. View at Publisher · View at Google Scholar
  24. D. Ristovski-Kornic, A. Stefanović, J. Kotur-Stevuljević et al., “Association of Myeloperoxidase and the Atherogenic Index of Plasma in Children with End-Stage Renal Disease,” Journal of Medical Biochemistry, vol. 36, no. 1, pp. 23–31, 2017. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Ece, F. Gürkan, M. Kervancıoğlu et al., “Oxidative stress, inflammation and early cardiovascular damage in children with chronic renal failure,” Pediatric Nephrology, vol. 21, no. 4, pp. 545–552, 2006. View at Publisher · View at Google Scholar
  26. E. Cavusoglu, C. Ruwende, C. Eng et al., “Usefulness of baseline plasma myeloperoxidase levels as an independent predictor of myocardial infarction at two years in patients presenting with acute coronary syndrome,” American Journal of Cardiology, vol. 99, no. 10, pp. 1364–1368, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. D. Lau and S. Baldus, “Myeloperoxidase and its contributory role in inflammatory vascular disease,” Pharmacology & Therapeutics, vol. 111, no. 1, pp. 16–26, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. L. Zhang, Y. Zhang, W. Zhong, C. Di, X. Lin, and Z. Xia, “Heme oxygenase-1 ameliorates dextran sulfate sodium-induced acute murine colitis by regulating Th17/Treg cell balance,” The Journal of Biological Chemistry, vol. 289, no. 39, pp. 26847–26858, 2014. View at Publisher · View at Google Scholar
  29. D. C. Baumgart and A. U. Dignass, “Intestinal barrier function,” Current Opinion in Clinical Nutrition & Metabolic Care, vol. 5, no. 6, pp. 685–694, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. M. A. Degli-Esposti and M. J. Smyth, “Close encounters of different kinds: dendritic cells and NK cells take centre stage,” Nature Reviews Immunology, vol. 5, no. 2, pp. 112–124, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. D. Gómez, N. Muñoz, R. Guerrero, O. Acosta, and C. A. Guerrero, “PPAR γ agonists as an anti-inflammatory treatment inhibiting rotavirus infection of small intestinal villi,” PPAR Research, vol. 2016, Article ID 4049373, 2016. View at Publisher · View at Google Scholar · View at Scopus
  32. H. Baumann and J. Gauldie, “The acute phase response,” Trends in Immunology, vol. 15, no. 2, pp. 74–80, 1994. View at Publisher · View at Google Scholar · View at Scopus
  33. B. Begue, H. Wajant, J.-C. Bambou et al., “Implication of TNF-related apoptosis-inducing ligand in inflammatory intestinal epithelial lesions,” Gastroenterology, vol. 130, no. 7, pp. 1962–1974, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. M. N. Ince and D. E. Elliott, “Immunologic and Molecular Mechanisms in Inflammatory Bowel Disease,” Surgical Clinics of North America, vol. 87, no. 3, pp. 681–696, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. J. Bauditz, S. Wedel, and H. Lochs, “Thalidomide reduces tumour necrosis factor-α and interleukin 12 production in patients with chronic active Crohn's disease,” Gut, vol. 50, no. 2, pp. 196–200, 2002. View at Publisher · View at Google Scholar · View at Scopus
  36. S. C. Ng, S. Plamondon, M. A. Kamm et al., “Immunosuppressive effects via human intestinal dendritic cells of probiotic bacteria and steroids in the treatment of acute ulcerative colitis,” Inflammatory Bowel Diseases, vol. 16, no. 8, pp. 1286–1298, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. Y. Liu, J. Peng, T. Sun, and et al., “Epithelial EZH2 serves as an epigenetic determinant in experimental colitis by inhibiting TNFalpha-mediated inflammation and apoptosis,” in Proceedings of the National Academy of Sciences, pp. E3796–E3805, 2017.
  38. R. Ravi, G. C. Bedi, L. W. Engstrom et al., “Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-κB,” Nature Cell Biology, vol. 3, no. 4, pp. 409–416, 2001. View at Publisher · View at Google Scholar · View at Scopus
  39. Y. Chen, H. Ma, D. Zhu et al., “Discovery of Novel Insulin Sensitizers: Promising Approaches and Targets,” PPAR Research, vol. 2017, pp. 1–13, 2017. View at Publisher · View at Google Scholar
  40. F. Rosa, J. S. Osorio, E. Trevisi, F. Yanqui-Rivera, C. T. Estill, and M. Bionaz, “2,4-Thiazolidinedione Treatment Improves the Innate Immune Response in Dairy Goats with Induced Subclinical Mastitis,” PPAR Research, vol. 2017, pp. 1–22, 2017. View at Publisher · View at Google Scholar
  41. L. Dubuquoy, C. Bourdon, M. Peuchmaur, and et al., “Peroxisome proliferator-activated receptor (PPAR) gamma: a new target for the treatment of inflammatory bowel disease,” Gastroenterologie Clinique Et Biologique, vol. 24, no. 8-9, pp. 719–724, 2000. View at Google Scholar
  42. Y. Kawahito, M. Kondo, Y. Tsubouchi et al., “15-deoxy-Δ12,14-PGJ2 induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats,” The Journal of Clinical Investigation, vol. 106, no. 2, pp. 189–197, 2000. View at Publisher · View at Google Scholar · View at Scopus
  43. C. Jiang, A. T. Ting, and B. Seed, “PPAR-γ agonists inhibit production of monocyte inflammatory cytokines,” Nature, vol. 391, no. 6662, pp. 82–86, 1998. View at Publisher · View at Google Scholar · View at Scopus
  44. H. S. P. Souza, C. J. A. Tortori, M. T. L. Castelo-Branco et al., “Apoptosis in the intestinal mucosa of patients with inflammatory bowel disease: evidence of altered expression of FasL and perforin cytotoxic pathways,” International Journal of Colorectal Disease, vol. 20, no. 3, pp. 277–286, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. R. Sreedhar, S. Arumugam, V. Karuppagounder et al., “Jumihaidokuto effectively inhibits colon inflammation and apoptosis in mice with acute colitis,” International Immunopharmacology, vol. 29, no. 2, pp. 957–963, 2015. View at Publisher · View at Google Scholar · View at Scopus